CGON - CG Oncology, Inc. Common stock
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$82.57
DETAILS
HIGH:
$93.00
LOW:
$70.00
MEDIAN:
$82.00
CONSENSUS:
$82.57
UPSIDE:
28.51%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | 4.0 | 1.1 | 0.2 | 0.2 | 10.4 |
| Cost of Revenue | 4.6 | 0 | 0 | 0.0 | 0.0 |
| Gross Profit | (0.6) | 1.1 | 0.2 | 0.2 | 10.3 |
| Operating Expenses | |||||
| R&D Expenses | 116.6 | 82.1 | 45.8 | 29.0 | 18.3 |
| SG&A Expenses | 73.5 | 33.7 | 9.9 | 6.4 | 4.6 |
| Other Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 190.2 | 115.8 | 55.7 | 35.4 | 23.0 |
| Operating Income | |||||
| Operating Income | (190.8) | (114.7) | (55.4) | (35.2) | (12.6) |
| Interest Expense | 0 | 0 | 0 | 0.0 | 0.5 |
| Interest Income | 0 | 26.6 | 6.9 | 0 | 0 |
| Profitability | |||||
| EBITDA | (159.6) | (114.6) | (55.4) | (35.2) | (12.4) |
| EBIT | (161.0) | (114.7) | (55.4) | (35.2) | (12.4) |
| Income Before Tax | (161.0) | (88.0) | (48.6) | (35.4) | (12.8) |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (161.0) | (88.0) | (48.6) | (35.4) | (12.8) |
| Per Share Data | |||||
| EPS (Basic) | -2.08 | -1.41 | -1.02 | -0.66 | -0.28 |
| EPS (Diluted) | -2.08 | -1.41 | -1.02 | -0.66 | -0.28 |
| Shares Outstanding | 77.3 | 62.5 | 66.6 | 66.6 | 66.6 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Current Assets | |||||
| Cash & Cash Equivalents | 32.5 | 257.1 | 8.3 | 88.1 | 53.6 |
| Short-Term Investments | 709.7 | 484.9 | 179.4 | 55.3 | 0 |
| Net Receivables | 0.7 | 0.8 | 0.1 | 0.3 | 0.0 |
| Inventory | 1.6 | 0 | 0 | 0 | 0 |
| Other Current Assets | 15.1 | 11.4 | 6.4 | 3.4 | 4.8 |
| Total Current Assets | 759.5 | 754.2 | 194.1 | 147.2 | 58.4 |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 19.6 | 0.5 | 0.5 | 0.5 | 0.2 |
| Goodwill | 10.3 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0.6 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.7 | 0.1 | 4.7 | 0.0 | 0.1 |
| Total Non-Current Assets | 32.1 | 0.6 | 5.2 | 0.5 | 0.3 |
| Total Assets | 791.6 | 754.8 | 199.3 | 147.7 | 58.7 |
| Current Liabilities | |||||
| Account Payables | 5.7 | 6.5 | 3.2 | 1.0 | 1.0 |
| Short-Term Debt | 0.9 | 0 | 0.6 | 9.0 | 2.9 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 24.2 | 0.4 | 0.5 | 0.2 | 1.1 |
| Total Current Liabilities | 30.8 | 21.4 | 14.3 | 15.4 | 6.0 |
| Non-Current Liabilities | |||||
| Long-Term Debt | 6.1 | 0 | 0 | 6.5 | 12.1 |
| Deferred Tax Liabilities | 0.3 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.7 | 0 | 0.0 | 0.4 | 0.4 |
| Total Non-Current Liabilities | 8.2 | 0.1 | 0.3 | 7.1 | 12.5 |
| Total Liabilities | 39.0 | 21.4 | 14.5 | 22.6 | 18.4 |
| Stockholders' Equity | |||||
| Common Stock | 0.0 | 0.0 | 0 | 0 | 0 |
| Retained Earnings | (379.0) | (218.0) | (129.9) | (81.3) | (45.9) |
| Accumulated Other Comprehensive Income | 0 | 0 | 0 | 0 | 0 |
| Total Stockholders' Equity | 752.6 | 733.4 | 184.8 | 125.2 | 40.3 |
| Total Liabilities & Equity | 791.6 | 754.8 | 199.3 | 147.7 | 58.7 |
| Debt Metrics | |||||
| Total Debt | 7.0 | 0.2 | 1.0 | 15.9 | 15.1 |
| Net Debt | (25.5) | (256.8) | (7.2) | (72.2) | (38.5) |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | (161.0) | (88.0) | (48.6) | (35.4) | (12.8) |
| Depreciation & Amortization | 1.4 | 0.0 | 0.0 | 0.0 | 0.0 |
| Stock-Based Compensation | 26.7 | 11.4 | 1.5 | 0.7 | 1.1 |
| Change in Working Capital | 2.3 | 2.9 | 3.4 | 4.4 | (2.0) |
| Other Non-Cash Items | (1.7) | (5.0) | (2.1) | 0.5 | 0.0 |
| Operating Cash Flow | (132.3) | (78.7) | (45.7) | (29.8) | (13.7) |
| Investing Activities | |||||
| Capital Expenditure | (0.1) | (0.2) | 0 | (0.0) | (0.1) |
| Acquisitions | (22.0) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (1,067.9) | (1,045.9) | (517.6) | (55.3) | 0 |
| Sales/Maturities of Investments | 844.1 | 745.4 | 396.4 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (245.8) | (300.8) | (121.2) | (55.4) | (0.1) |
| Financing Activities | |||||
| Net Debt Issuance | 0 | (0.4) | (16.3) | 0 | 15.2 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (0.8) | (1.3) | 0 | 0 |
| Financing Cash Flow | 153.6 | 628.3 | 87.0 | 119.7 | 15.4 |
| Cash Position | |||||
| Net Change in Cash | (224.6) | 248.8 | (79.9) | 34.5 | 1.7 |
| Cash at Beginning | 257.1 | 8.3 | 88.1 | 53.6 | 51.9 |
| Cash at End | 32.5 | 257.1 | 8.3 | 88.1 | 53.6 |
| Free Cash Flow | (132.5) | (78.9) | (45.7) | (29.8) | (13.8) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 4.0 | 1.1 | 0.2 | 0.2 | 10.4 |
| Gross Profit | (0.6) | 1.1 | 0.2 | 0.2 | 10.3 |
| Operating Income | (190.8) | (114.7) | (55.4) | (35.2) | (12.6) |
| Net Income | (161.0) | (88.0) | (48.6) | (35.4) | (12.8) |
| EPS (Diluted) | -2.08 | -1.41 | -1.02 | -0.66 | -0.28 |
| Balance Sheet | |||||
| Cash & Equivalents | 32.5 | 257.1 | 8.3 | 88.1 | 53.6 |
| Total Assets | 791.6 | 754.8 | 199.3 | 147.7 | 58.7 |
| Total Debt | 7.0 | 0.2 | 1.0 | 15.9 | 15.1 |
| Stockholders' Equity | 752.6 | 733.4 | 184.8 | 125.2 | 40.3 |
| Cash Flow | |||||
| Operating Cash Flow | (132.3) | (78.7) | (45.7) | (29.8) | (13.7) |
| Capital Expenditure | (0.1) | (0.2) | 0 | (0.0) | (0.1) |
| Free Cash Flow | (132.5) | (78.9) | (45.7) | (29.8) | (13.8) |